Low Dose Aspirin Therapy Decreases Blood Glucose Levels but Does not Prevent Type I Diabetes-induced Bone Loss

Coe, Lindsay M.; Denison, Jeffery D.; McCabe, Laura R.

doi:10.1159/000335806

Cited by 14 publications

(11 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies documented that Aspirin can significantly decrease blood glucose level 16 which is in agree with our findings in this study. It is claimed that Aspirin can cause decrease in basal rates of hepatic glucose production, enhances tissue insulin sensitivity, decreases insulin clearance, and decreases oxidative stress in diabetic patients 17,18 .…”

Section: Discussionsupporting

confidence: 94%

Pharmacodynamics Drug Interactions of Metformin with Aspirin and Nifedipine

Hassan¹,

Mudawi²,

Sulaiman³

2016

AJPRHC

View full text Add to dashboard Cite

Metformin is now being recognized as the standard therapy in T2D patients who are overweight. Metformin has many drug-disease interactions that can increase the risk of metformin-associated lactic acidosis. Therefore this study was conducted to evaluate any possible pharmacodynamic interactions between metformin and drugs used to treat chronic diseases e.g. Hypertension. The rats were fasted overnight before inducing diabetes with streptozotocin. The rats were given an intraperitoneal injection of streptozotocin (50 mg kg−1) freshly prepared in 0.1M sodium citrate buffer. The diabetic state was confirmed 72 h after streptozotocin injection. Diabetic rats were grouped into seven groups each group of five rats and distributed among the normal control group diabetic control group and the treatment groups. The treatment continued for 10 days. Blood samples were taken before treatment and after 10 days and analyzed for serum glucose, cholesterol, HDL, LDL, and triglycerides. In the diabetic control group which was given STZ alone the blood glucose level decreased significantly (p < 0.05) after 10 days but still above the hyperglycemic level (200mg/dl). The same was observed in the group treated with metformin. The group treated with nifedipine and aspirin showed significant reduction (p < 0.01) in the glucose level below the hyperglycemic level (200mg/dl). While the groups treated with (Metformin + Nifedipine) and (Metformin +Aspirin) showed highly significant reduction (P<0.001) in blood glucose level. These results conclude that the combination of (metformin +Nifedipine) and the combination of (Metformin + Aspirin) have highly significant hypoglycemic effect. It also showed that Nifedipine has promising role in reducing blood glucose level, lipid profile especially LDL-cholesterol, and body weight.

show abstract

Section: Discussionsupporting

confidence: 94%

Pharmacodynamics Drug Interactions of Metformin with Aspirin and Nifedipine

Hassan¹,

Mudawi²,

Sulaiman³

2016

AJPRHC

View full text Add to dashboard Cite

show abstract

“…The water was available ad libitum . The bottles were replaced every morning with fresh water or drug solution, and the residual volume of water in bottles was measured to assure that the mice drank the intended water volume [17], [18]. The treatment was initiated 48 hours after parasite inoculation, for 20 days at the doses indicated in each figure.…”

Section: Methodsmentioning

confidence: 99%

Protective Role of Acetylsalicylic Acid in Experimental Trypanosoma cruzi Infection: Evidence of a 15-epi-Lipoxin A4-Mediated Effect

et al. 2013

View full text Add to dashboard Cite

Chagas' disease, produced by Trypanosoma cruzi, affects more than 8 million people, producing approximately 10,000 deaths each year in Latin America. Migration of people from endemic regions to developed countries has expanded the risk of infection, transforming this disease into a globally emerging problem. PGE2 and other eicosanoids contribute to cardiac functional deficits after infection with T. cruzi. Thus, the inhibition of host cyclooxygenase (COX) enzyme emerges as a potential therapeutic target. In vivo studies about the effect of acetylsalicylic acid (ASA) upon T. cruzi infection are controversial, and always report the effect of ASA at a single dose. Therefore, we aimed to analyze the effect of ASA at different doses in an in vivo model of infection and correlate it with the production of arachidonic acid metabolites. ASA decreased mortality, parasitemia, and heart damage in T. cruzi (Dm28c) infected mice, at the low doses of 25 and 50 mg/Kg. However, this effect disappeared when the high ASA doses of 75 and 100 mg/Kg were used. We explored whether this observation was related to the metabolic shift toward the production of 5-lipoxygenase derivatives, and although we did not observe an increase in LTB4 production in infected RAW cells and mice infected, we did find an increase in 15-epi-LXA4 (an ASA-triggered lipoxin). We also found high levels of 15-epi-LXA4 in T. cruzi infected mice treated with the low doses of ASA, while the high ASA doses decreased 15-epi-LXA4 levels. Importantly, 15-epi-LXA4 prevented parasitemia, mortality, and cardiac changes in vivo and restored the protective role in the treatment with a high dose of ASA. This is the first report showing the production of ASA-triggered lipoxins in T. cruzi infected mice, which demonstrates the role of this lipid as an anti-inflammatory molecule in the acute phase of the disease.

show abstract

“…Also, it was demonstrated that the use of a non-selective COX inhibitor (Ketorolac) led to a delay in the fracture healing, but on the 35th day, all fractures (control and test groups) showed union [ 29 ]. Simon and collaborators [ 30 ] also demonstrated in an animal model of a bone repair study that NSAIDs can be a negative interference during the early stages of fracture union, leading to a reduction of fracture callus mechanical properties when administered during the initial stages of healing is performed.…”

Section: Discussionmentioning

confidence: 99%

Effects of low-dose aspirin on the osseointegration process in rats

et al. 2021

View full text Add to dashboard Cite

Background Several drugs are capable of promoting changes in bone metabolism. The aim of this study was to evaluate the effect of long-term low-dose aspirin (LDA) therapy on implant osseointegration. Methods Male Wistar rats were divided into 4 groups (n = 8/group) according to oral gavage solution received prior (42 days) to the implant surgery on the tibia. The control group was treated with saline solution for 7 (CG-7) and 28 (CG-28) days. The use of low-dose aspirin was performed in AG groups (6.75 mg/kg of aspirin) for 7 (AG-7) and 28 (AG-28) days. After experimental periods, histomorphometric evaluation of bone-to-implant contact (BIC) and the bone area between threads (BABT) was performed. Results Reduced BIC values were detected in AG-7 (62.8% ± 17.1) group compared to AG-28 (91.9% ± 5.4), CG-7 (82.7% ± 15.2), and CG-28 (89.9% ± 9.7). BABT evaluation revealed lower values in AG-7 (70.9% ± 15.2) compared to AG-28 (95.4% ± 3.7) and CG-28 (87.1% ± 10.2) groups. Conclusions The treatment with low doses of aspirin promoted a discrete inhibitory effect in the early stages (7 days) of repair after implant placement, specifically in the bone deposition. However, these effects were not detected in the late stages (28 days), considering BIC and BABT parameters.

show abstract

Low Dose Aspirin Therapy Decreases Blood Glucose Levels but Does not Prevent Type I Diabetes-induced Bone Loss

Cited by 14 publications

References 60 publications

Pharmacodynamics Drug Interactions of Metformin with Aspirin and Nifedipine

Pharmacodynamics Drug Interactions of Metformin with Aspirin and Nifedipine

Protective Role of Acetylsalicylic Acid in Experimental Trypanosoma cruzi Infection: Evidence of a 15-epi-Lipoxin A4-Mediated Effect

Effects of low-dose aspirin on the osseointegration process in rats

Contact Info

Product

Resources

About